NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price & News $18.31 -0.19 (-1.03%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$18.15▼$18.9050-Day Range$18.08▼$23.4552-Week Range$17.80▼$41.93Volume822,236 shsAverage Volume1.03 million shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$49.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Amylyx Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside169.8% Upside$49.40 Price TargetShort InterestBearish19.10% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.65Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth164.66%From $1.16 to $3.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector157th out of 971 stocksPharmaceutical Preparations Industry50th out of 443 stocks 3.5 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.40, Amylyx Pharmaceuticals has a forecasted upside of 169.8% from its current price of $18.31.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.10% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 4.20%, indicating that investor sentiment is decreasing. Previous Next 0.8 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Amylyx Pharmaceuticals will have a dividend payout ratio of 33.09% next year. This indicates that Amylyx Pharmaceuticals will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 2.0 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amylyx Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.80% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.70% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow by 164.66% in the coming year, from $1.16 to $3.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -14.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -14.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmylyx Pharmaceuticals has a PEG Ratio of 0.24. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amylyx Pharmaceuticals (NASDAQ:AMLX) StockAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More AMLX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Stock News HeadlinesSeptember 29, 2023 | finance.yahoo.com25 Biggest Stocks with Negative BetaSeptember 29, 2023 | finance.yahoo.com14 Best Depressed Stocks To Buy NowOctober 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 20, 2023 | finance.yahoo.comMarinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?September 11, 2023 | seekingalpha.comAmylyx Pharmaceuticals: A High Risk/High Reward StockAugust 22, 2023 | finance.yahoo.comThe past year for Amylyx Pharmaceuticals (NASDAQ:AMLX) investors has not been profitableAugust 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Galecto (GLTO), Amylyx Pharmaceuticals Inc (AMLX)August 14, 2023 | finance.yahoo.comAmylyx's new ALS drug has turned a profit for six months straightOctober 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 13, 2023 | finance.yahoo.comAMLX - Amylyx Pharmaceuticals, Inc.August 13, 2023 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finance.yahoo.comQ2 2023 Amylyx Pharmaceuticals Inc Earnings CallAugust 11, 2023 | seekingalpha.comAmylyx Achieves Profitability On Wings Of Relyvrio (Rating Upgrade)August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioNTech SE (BNTX) and Bright Health Group (BHG)August 11, 2023 | seekingalpha.comAmylyx Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 11, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comAmylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023July 28, 2023 | markets.businessinsider.comAmylyx Pharmaceuticals Inc (AMLX) Gets a Buy from Mizuho SecuritiesJuly 28, 2023 | finance.yahoo.comGoldman Sachs Predicts up to 120% Rally for These 2 Stocks — Here’s Why They Have Solid UpsideJuly 27, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Amylyx Pharmaceuticals Inc (AMLX)July 24, 2023 | markets.businessinsider.comAmylyx Stock Has A Good Entry Point, Says Bullish Goldman SachsJuly 24, 2023 | finance.yahoo.comWhy Shares of Amylyx Pharmaceuticals Were Up MondayJuly 18, 2023 | finance.yahoo.com3 Stocks Worth a Buy for Remarkable Earnings AccelerationJuly 12, 2023 | finance.yahoo.comAmylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) ProgramJune 26, 2023 | markets.businessinsider.comMizuho Securities Sticks to Their Buy Rating for Amylyx Pharmaceuticals Inc (AMLX)June 23, 2023 | msn.comEMA panel gives negative opinion on Amylix ALS drug applicationJune 23, 2023 | markets.businessinsider.comAmylyx Pharma: CHMP Adopts Negative Opinion On Conditional Marketing Authorisation Of AMX0035See More Headlines Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees338Year FoundedN/APrice Target and Rating Average Stock Price Forecast$49.40 High Stock Price Forecast$50.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+169.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E Ratio15.78 P/E Growth0.24Net Income$-198,380,000.00 Net Margins-37.95% Pretax Margin-36.79% Return on Equity-23.80% Return on Assets-20.30% Debt Debt-to-Equity RatioN/A Current Ratio6.67 Quick Ratio6.28 Sales & Book Value Annual Sales$191.87 million Price / Sales6.43 Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book3.56Miscellaneous Outstanding Shares67,378,000Free Float59,427,000Market Cap$1.23 billion OptionableNot Optionable Beta-0.93 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Joshua B. Cohen (Age 31)Co-Founder, Co-CEO & Director Comp: $1MMr. Justin B. Klee (Age 32)Co-Founder, Co-CEO & Director Comp: $1MMr. James M. Frates M.B.A. (Age 56)Chief Financial Officer Comp: $695.12kMs. Gina M. Mazzariello (Age 52)Chief Legal Officer & Gen. Counsel Comp: $794.83kMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Debra L. Canner (Age 64)Global Head of HR & CHRO Ms. Margaret M. Olinger M.B.A (Age 58)Global Head of Commercial & Chief Commercial Officer Dr. Patrick D. Yeramian M.D. (Age 64)MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer More ExecutivesKey CompetitorsSage TherapeuticsNASDAQ:SAGECatalyst PharmaceuticalsNASDAQ:CPRXStructure TherapeuticsNASDAQ:GPCRSummit TherapeuticsNASDAQ:SMMTAmneal PharmaceuticalsNYSE:AMRXView All CompetitorsInsiders & InstitutionsTucker Asset Management LLCBought 5,129 shares on 9/8/2023Ownership: 0.013%Perceptive Advisors LLCSold 1,160,725 shares on 8/24/2023Ownership: 7.233%California State Teachers Retirement SystemBought 24,545 shares on 8/21/2023Ownership: 0.064%Osaic Holdings Inc.Bought 2,200 shares on 8/21/2023Ownership: 0.005%Nuveen Asset Management LLCSold 58,858 shares on 8/16/2023Ownership: 0.821%View All Insider TransactionsView All Institutional Transactions AMLX Stock - Frequently Asked Questions Should I buy or sell Amylyx Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMLX shares. View AMLX analyst ratings or view top-rated stocks. What is Amylyx Pharmaceuticals' stock price forecast for 2023? 5 brokerages have issued 1 year price objectives for Amylyx Pharmaceuticals' stock. Their AMLX share price forecasts range from $48.00 to $50.00. On average, they predict the company's share price to reach $49.40 in the next year. This suggests a possible upside of 169.8% from the stock's current price. View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts. How have AMLX shares performed in 2023? Amylyx Pharmaceuticals' stock was trading at $36.95 at the start of the year. Since then, AMLX stock has decreased by 50.4% and is now trading at $18.31. View the best growth stocks for 2023 here. When is Amylyx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our AMLX earnings forecast. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its earnings results on Thursday, August, 10th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.30. The company had revenue of $98.22 million for the quarter, compared to analysts' expectations of $84.30 million. Amylyx Pharmaceuticals had a negative net margin of 37.95% and a negative trailing twelve-month return on equity of 23.80%. What ETFs hold Amylyx Pharmaceuticals' stock? ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE). Is Amylyx Pharmaceuticals a good dividend stock? Amylyx Pharmaceuticals (NASDAQ:AMLX) pays an annual dividend of $1.02 per share and currently has a dividend yield of 0.00%. When did Amylyx Pharmaceuticals IPO? (AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. What is Amylyx Pharmaceuticals' stock symbol? Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX." How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amylyx Pharmaceuticals' stock price today? One share of AMLX stock can currently be purchased for approximately $18.31. How much money does Amylyx Pharmaceuticals make? Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.23 billion and generates $191.87 million in revenue each year. The company earns $-198,380,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. How many employees does Amylyx Pharmaceuticals have? The company employs 338 workers across the globe. How can I contact Amylyx Pharmaceuticals? The official website for the company is amylyx.com. The company can be reached via phone at 617-682-0917 or via email at investors@amylyx.com. This page (NASDAQ:AMLX) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.